Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study

被引：4
|
作者：
Xu, R-H. [1 ]
Oh, D-Y. [2 ]
Kato, K. [3 ]
Arkenau, T. [4 ]
Tabernero, J. [5 ]
Cruz-Correa, M. [6 ]
Zimina, A. [7 ]
Bai, Y. [8 ]
Shi, J. [9 ]
Lee, K-W. [10 ]
Hirano, H.
Spigel, D. R. [11 ]
Wyrwicz, L. S. [12 ]
Cid, R. A. Pazo [13 ]
Li, L. [14 ]
Xu, Y. [15 ]
McHenry, M. B. [16 ]
Yang, S. [14 ]
Moehler, M. [17 ]
机构：
[1] Sun Yat Sen Univ, Dept Med Oncol, Collaborat Innovat Ctr Canc Med, Canc Ctr,State Key Lab Oncol South China, Guangzhou, Peoples R China
[2] Seoul Natl Univ, Hosp Canc Res Inst, Dept Internal Med, Coll Med, Seoul, South Korea
[3] Natl Canc Ctr, Dept Gastrointestinal Med Oncol, Tokyo, Japan
[4] Sarah Cannon Res Inst, Dept Drug Dev, London, England
[5] Vall dHebron Hosp Campus & Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain
[6] Univ Puerto Rico, Sch Med, San Juan, PR USA
[7] BIH Omsk Region, Dept Oncol, Clin Oncol Dispensary, Omsk, Russia
[8] Harbin Med Univ, Dept Gastrointestinal Oncol, Canc Hosp, Harbin, Peoples R China
[9] Linyi Canc Hosp, Dept Med Oncol 2, Linyi, Shandong, Peoples R China
[10] Seoul Natl Univ, Coll Med, Dept Internal Med, Bundang Hosp, Seongnam, Gyeonggi Do, South Korea
[11] Tennessee Oncol, Dept Thorac Med Oncol, Nashville, TN USA
[12] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Oncol & Radiotherapy, Warsaw, Poland
[13] Hosp Univ Miguel Servet, Dept Med Oncol, Zaragoza, Spain
[14] BeiGene Beijing Co Ltd, Clin Dev Clin Biomarker, Beijing, Peoples R China
[15] BeiGene Shanghai Co Ltd, Clin Dev, Shanghai, Peoples R China
[16] BeiGene USA Inc, GSDS, Cambridge, MA USA
[17] Johannes Gutenberg Univ Clin, Dept Internal Med 1, Mainz, Germany
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.081
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA80
引用
收藏
页码：S1320 / S1321
页数：2
相关论文
共 50 条
  • [31] First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305
    Moehler, Markus
    Oh, Do-Youn
    Kato, Ken
    Arkenau, Tobias
    Tabernero, Josep
    Lee, Keun-Wook
    Rha, Sun Young
    Hirano, Hidekazu
    Spigel, David
    Yamaguchi, Kensei
    Wyrwicz, Lucjan
    Disel, Umut
    Pazo-Cid, Roberto A.
    Fornaro, Lorenzo
    Xu, Yaling
    Sheng, Tao
    Yang, Silu
    Kadva, Alysha
    Cruz-Correa, Marcia
    Xu, Rui-Hua
    ADVANCES IN THERAPY, 2025, : 2248 - 2268
  • [32] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 4-year (yr) follow-up
    Shen, Lin
    Bai, Yuxian
    Lin, Xiaoyan
    Li, Wei
    Wang, Jufeng
    Zhang, Xiaochun
    Pan, Hongming
    Bai, Chunmei
    Bai, Li
    Cheng, Ying
    Zhang, Jingdong
    Zhong, Haijun
    Ba, Yi
    Hu, Wenwei
    Xu, Rui-Hua
    Guo, Weijian
    Qin, Shukui
    Wang, Rui
    McCraith, Stephen
    Liu, Tianshu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 318 - 318
  • [33] RATIONALE 307: A Subgroup Analysis of Tislelizumab Plus Chemo vs Chemo Alone As 1L Treatment for Stage IIIB Advanced Sq NSCLC
    Lu, S.
    Yu, X.
    Wang, J.
    Zhao, J.
    Yu, Y.
    Hu, C.
    Feng, G.
    Ying, K.
    Zhuang, W.
    Zhou, J.
    Wu, J.
    Leaw, S. J.
    Bai, F.
    Lin, X.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1019 - S1020
  • [34] Randomized, global, phase III study of tislelizumab (TIS) plus chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup
    Kato, K.
    Yoon, H.
    Raymond, E.
    Hubner, R.
    Shu, Y.
    Pan, Y.
    Park, S. R.
    Ping, L.
    Jiang, Y.
    Zhang, J.
    Wu, X.
    Yao, Y.
    Shen, L.
    Kojima, T.
    Lin, C-Y.
    Wang, L.
    Tao, A.
    Peng, Y.
    Li, L.
    Xu, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S1458 - S1458
  • [35] Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma
    Xu, Jianming
    Bai, Yuxian
    Xu, Nong
    Li, Enxiao
    Wang, Buhai
    Wang, Jin
    Li, Xiang
    Wang, Xin
    Yuan, Xianglin
    CLINICAL CANCER RESEARCH, 2020, 26 (17) : 4542 - 4550
  • [36] Response characteristics of tislelizumab (TIS) plus chemotherapy (chemo) in first-line (1L) treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): A post hoc analysis of RATIONALE-306.
    Li, Yi
    Zhao, Chuanhua
    Liu, Rongrui
    Xu, Sheng
    Miao, Xiaojie
    Xu, Jianming
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 413 - 413
  • [37] First-line nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 2-year follow-up
    Shen, L.
    Bai, Y.
    Lin, X.
    Li, W.
    Wang, J.
    Zhang, X.
    Pan, H.
    Bai, C.
    Bai, L.
    Cheng, Y.
    Zhang, J.
    Zhong, H.
    Ba, Y.
    Hu, W.
    Xu, R.
    Guo, W.
    Qin, S.
    Yang, N.
    Lu, J.
    Chanaga, C. Amaya
    Soleymani, S.
    Liu, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S279 - S279
  • [38] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649.
    Shen, Lin
    Bai, Yuxian
    Lin, Xiaoyan
    Li, Wei
    Wang, Jufeng
    Zhang, Xiaochun
    Pan, Hongming
    Bai, Chunmei
    Bai, Li
    Cheng, Ying
    Zhang, Jingdong
    Zhong, Haijun
    Ba, Yi
    Hu, Wenwei
    Xu, Rui-Hua
    Guo, Weijian
    Qin, Shukui
    Hu, Nan
    McCraith, Stephen
    Liu, Tianshu
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 392 - 392
  • [39] Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: perspectives from the United States and China
    Lang, Wenwang
    Ai, Qi
    Zhang, Wenwen
    Jiang, Qinling
    He, Yulong
    Ouyang, Ming
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [40] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma
    Xu, Rui-hua
    Arkenau, Hendrik-Tobias
    Bang, Yung-Jue
    Denlinger, Crystal S.
    Kato, Ken
    Tabernero, Josep
    Wang, Jin
    Li, Jiang
    Castro, Henry
    Moehler, Markus H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
12345